With the FDA’s rule in place, sponsors now have clearer regulatory footing to submit nonclinical data generated through validated alternative methods as part of IND and marketing applications, though ...
Jaenisch, Muraru, and Pandey debate whether AI "slop" is infiltrating pharma SOPs and deviation reports and who should catch it first.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results